Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK.
<h4>Objectives</h4>Proton pump inhibitors (PPIs) are commonly prescribed for prevention and treatment of gastrointestinal conditions or for gastroprotection from other drugs. Research suggests they are linked to increased dementia risk. We use linked national health data to examine the a...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0237676 |
| _version_ | 1819280228289085440 |
|---|---|
| author | Roxanne Cooksey Jonathan Kennedy Michael S Dennis Valentina Escott-Price Ronan A Lyons Michael Seaborne Sinead Brophy |
| author_facet | Roxanne Cooksey Jonathan Kennedy Michael S Dennis Valentina Escott-Price Ronan A Lyons Michael Seaborne Sinead Brophy |
| author_sort | Roxanne Cooksey |
| collection | DOAJ |
| description | <h4>Objectives</h4>Proton pump inhibitors (PPIs) are commonly prescribed for prevention and treatment of gastrointestinal conditions or for gastroprotection from other drugs. Research suggests they are linked to increased dementia risk. We use linked national health data to examine the association between PPI use and the development of incident dementia.<h4>Methods and findings</h4>A population-based study using electronic health-data from the Secure Anonymised Information Linkage (SAIL) Databank, Wales (UK) from 1999 to 2015. Of data available on 3,765,744 individuals, a cohort who had ever been prescribed a PPI was developed (n = 183,968) for people aged 55 years and over and compared to non-PPI exposed individuals (131,110). Those with prior dementia, mild-cognitive-impairment or delirium codes were excluded. Confounding factors included comorbidities and/or drugs associated with them. Comorbidities might include head injury and some examples of medications include antidepressants, antiplatelets and anticoagulants. These commonly prescribed drugs were investigated as it was not feasible to explore all drugs in this study. The main outcome was a diagnosis of incident dementia. Cox proportional hazard regression modelling was used to calculate the Hazard ratio (HR) of developing dementia in PPI-exposed compared to unexposed individuals while controlling for potential confounders. The mean age of the PPI exposed individuals was 69.9 years and 39.8% male while the mean age of the unexposed individuals was 72.1 years and 41.1% male. The rate of PPI usage was 58.4% (183,968) and incident dementia rate was 11.8% (37,148/315,078). PPI use was associated with decreased dementia risk (HR: 0.67, 95% CI: 0.65 to 0.67, p<0.01).<h4>Conclusions</h4>This study, using large-scale, multi-centre health-data was unable to confirm an association between PPI use and increased dementia risk. Previously reported links may be associated with confounders of people using PPI's, such as increased risk of cardiovascular disease and/or depression and their associated medications which may be responsible for any increased risk of developing dementia. |
| first_indexed | 2024-12-24T00:40:28Z |
| format | Article |
| id | doaj.art-599abd8f745a4ae7ad70cf1d48078094 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-24T00:40:28Z |
| publishDate | 2020-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-599abd8f745a4ae7ad70cf1d480780942022-12-21T17:23:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01159e023767610.1371/journal.pone.0237676Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK.Roxanne CookseyJonathan KennedyMichael S DennisValentina Escott-PriceRonan A LyonsMichael SeaborneSinead Brophy<h4>Objectives</h4>Proton pump inhibitors (PPIs) are commonly prescribed for prevention and treatment of gastrointestinal conditions or for gastroprotection from other drugs. Research suggests they are linked to increased dementia risk. We use linked national health data to examine the association between PPI use and the development of incident dementia.<h4>Methods and findings</h4>A population-based study using electronic health-data from the Secure Anonymised Information Linkage (SAIL) Databank, Wales (UK) from 1999 to 2015. Of data available on 3,765,744 individuals, a cohort who had ever been prescribed a PPI was developed (n = 183,968) for people aged 55 years and over and compared to non-PPI exposed individuals (131,110). Those with prior dementia, mild-cognitive-impairment or delirium codes were excluded. Confounding factors included comorbidities and/or drugs associated with them. Comorbidities might include head injury and some examples of medications include antidepressants, antiplatelets and anticoagulants. These commonly prescribed drugs were investigated as it was not feasible to explore all drugs in this study. The main outcome was a diagnosis of incident dementia. Cox proportional hazard regression modelling was used to calculate the Hazard ratio (HR) of developing dementia in PPI-exposed compared to unexposed individuals while controlling for potential confounders. The mean age of the PPI exposed individuals was 69.9 years and 39.8% male while the mean age of the unexposed individuals was 72.1 years and 41.1% male. The rate of PPI usage was 58.4% (183,968) and incident dementia rate was 11.8% (37,148/315,078). PPI use was associated with decreased dementia risk (HR: 0.67, 95% CI: 0.65 to 0.67, p<0.01).<h4>Conclusions</h4>This study, using large-scale, multi-centre health-data was unable to confirm an association between PPI use and increased dementia risk. Previously reported links may be associated with confounders of people using PPI's, such as increased risk of cardiovascular disease and/or depression and their associated medications which may be responsible for any increased risk of developing dementia.https://doi.org/10.1371/journal.pone.0237676 |
| spellingShingle | Roxanne Cooksey Jonathan Kennedy Michael S Dennis Valentina Escott-Price Ronan A Lyons Michael Seaborne Sinead Brophy Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. PLoS ONE |
| title | Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. |
| title_full | Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. |
| title_fullStr | Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. |
| title_full_unstemmed | Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. |
| title_short | Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. |
| title_sort | proton pump inhibitors and dementia risk evidence from a cohort study using linked routinely collected national health data in wales uk |
| url | https://doi.org/10.1371/journal.pone.0237676 |
| work_keys_str_mv | AT roxannecooksey protonpumpinhibitorsanddementiariskevidencefromacohortstudyusinglinkedroutinelycollectednationalhealthdatainwalesuk AT jonathankennedy protonpumpinhibitorsanddementiariskevidencefromacohortstudyusinglinkedroutinelycollectednationalhealthdatainwalesuk AT michaelsdennis protonpumpinhibitorsanddementiariskevidencefromacohortstudyusinglinkedroutinelycollectednationalhealthdatainwalesuk AT valentinaescottprice protonpumpinhibitorsanddementiariskevidencefromacohortstudyusinglinkedroutinelycollectednationalhealthdatainwalesuk AT ronanalyons protonpumpinhibitorsanddementiariskevidencefromacohortstudyusinglinkedroutinelycollectednationalhealthdatainwalesuk AT michaelseaborne protonpumpinhibitorsanddementiariskevidencefromacohortstudyusinglinkedroutinelycollectednationalhealthdatainwalesuk AT sineadbrophy protonpumpinhibitorsanddementiariskevidencefromacohortstudyusinglinkedroutinelycollectednationalhealthdatainwalesuk |